Published in Ann Med on January 01, 2005
Comparative genetics of the central nervous system in epigean and hypogean Astyanax mexicanus. Genetica (2011) 0.90
ABC of obesity. Management: part II--drugs. BMJ (2006) 0.85
Dissociable effects of CB1 receptor blockade on anxiety-like and consummatory behaviors in the novelty-induced hypophagia test in mice. Psychopharmacology (Berl) (2013) 0.83
Constitutive basal and stimulated human small bowel contractility is enhanced in obesity. Ann Surg Innov Res (2009) 0.80
Cannabinoid type 1 receptor mediates depot-specific effects on differentiation, inflammation and oxidative metabolism in inguinal and epididymal white adipocytes. Nutr Diabetes (2011) 0.78
Plasma and liver lipidomics response to an intervention of rimonabant in ApoE*3Leiden.CETP transgenic mice. PLoS One (2011) 0.78
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome. Core Evid (2008) 0.76
Treatment options for obesity and potential therapies on the horizon. P T (2011) 0.75
The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest (2003) 3.62
The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev (2005) 2.90
Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab (2006) 2.72
Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2013) 2.43
Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity. J Clin Endocrinol Metab (2005) 1.73
The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome. Ann N Y Acad Sci (2006) 1.53
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril (2008) 1.44
CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab (2010) 1.33
Effect of flutamide and metformin administered alone or in combination in dieting obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2004) 1.29
Requirement of cannabinoid receptor type 1 for the basal modulation of hypothalamic-pituitary-adrenal axis function. Endocrinology (2006) 1.27
Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes (2008) 1.25
Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab (2006) 1.19
Stress-related development of obesity and cortisol in women. Obesity (Silver Spring) (2009) 1.14
Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors. Diabetes (2004) 1.14
Body mass index-independent metabolic alterations in narcolepsy with cataplexy. Sleep (2009) 1.13
The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol (2010) 1.12
Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol Med (2011) 1.07
Serum steroid profiling by isotopic dilution-liquid chromatography-mass spectrometry: comparison with current immunoassays and reference intervals in healthy adults. Steroids (2010) 1.06
Clomiphene citrate, metformin or both as first-step approach in treating anovulatory infertility in patients with polycystic ovary syndrome (PCOS): a systematic review of head-to-head randomized controlled studies and meta-analysis. Clin Endocrinol (Oxf) (2008) 1.01
Comment: response of the hypothalamic-pituitary-adrenocortical axis to high-protein/fat and high-carbohydrate meals in women with different obesity phenotypes. J Clin Endocrinol Metab (2002) 0.98
Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. J Clin Endocrinol Metab (2014) 0.97
Cortisol, energy intake, and food frequency in overweight/obese women. Nutrition (2010) 0.96
Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab (2012) 0.96
Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. Eur J Endocrinol (2012) 0.96
Sex difference in the relationship between the hypothalamic-pituitary-adrenal axis and sex hormones in obesity. Obesity (Silver Spring) (2006) 0.95
Here, there and everywhere: the endocannabinoid system. J Neuroendocrinol (2008) 0.95
Estimation of reference intervals of five endocannabinoids and endocannabinoid related compounds in human plasma by two dimensional-LC/MS/MS. J Lipid Res (2011) 0.94
Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome. J Clin Endocrinol Metab (2006) 0.93
Circulating obestatin levels and the ghrelin/obestatin ratio in obese women. Eur J Endocrinol (2007) 0.93
Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. Otolaryngol Head Neck Surg (2007) 0.93
Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome. J Clin Endocrinol Metab (2010) 0.93
Predictors of weight loss and maintenance in patients treated with antiobesity drugs. Diabetes Metab Syndr Obes (2011) 0.92
Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab (2013) 0.89
Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) (2013) 0.89
[Pharmacological therapy of obesity]. G Ital Cardiol (Rome) (2008) 0.88
Plasma ghrelin, obesity, and the polycystic ovary syndrome: correlation with insulin resistance and androgen levels. J Clin Endocrinol Metab (2002) 0.88
Active and total ghrelin concentrations in the newborn. J Pediatr Endocrinol Metab (2005) 0.88
Ghrelin and reproductive disorders. Mol Cell Endocrinol (2011) 0.87
Polycystic ovary syndrome is a risk factor for type 2 diabetes: results from a long-term prospective study. Diabetes (2012) 0.87
Fighting obesity and associated risk factors by antagonising cannabinoid type 1 receptors. Lancet (2005) 0.87
A combination of polymorphisms in HSD11B1 associates with in vivo 11{beta}-HSD1 activity and metabolic syndrome in women with and without polycystic ovary syndrome. Eur J Endocrinol (2011) 0.87
Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab (2003) 0.86
Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol Head Neck Surg (2013) 0.86
Maternal polycystic ovary syndrome may be associated with adverse pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol (2010) 0.85
Prevalence of functional disorders of androgen excess in unselected premenopausal women: a study in blood donors. Hum Reprod (2012) 0.85
Plasma acylated ghrelin levels are higher in patients with chronic atrophic gastritis. Clin Endocrinol (Oxf) (2007) 0.84
(11)C-meta-hydroxyephedrine PET/CT imaging allows in vivo study of adaptive thermogenesis and white-to-brown fat conversion. Mol Metab (2013) 0.83
Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases. Curr Opin Pharmacol (2006) 0.83
Familial partial lipodystrophy, mandibuloacral dysplasia and restrictive dermopathy feature barrier-to-autointegration factor (BAF) nuclear redistribution. Cell Cycle (2012) 0.83
Functional effects of polymorphisms in the human gene encoding 11 beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1): a sequence variant at the translation start of 11 beta-HSD1 alters enzyme levels. Endocrinology (2009) 0.83
Steroids and the metabolic syndrome. J Steroid Biochem Mol Biol (2008) 0.83
Emerging concepts about prenatal genesis, aberrant metabolism and treatment paradigms in polycystic ovary syndrome. Endocrine (2012) 0.82
I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report. Clin Nucl Med (2011) 0.82
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 0.81
Common variants in the sex hormone-binding globulin gene (SHBG) and polycystic ovary syndrome (PCOS) in Mediterranean women. Hum Reprod (2012) 0.80
Role of sex hormones in modulation of brown adipose tissue activity. J Mol Endocrinol (2012) 0.80
Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. J Clin Endocrinol Metab (2013) 0.80
The empowerment of translational research: lessons from laminopathies. Orphanet J Rare Dis (2012) 0.80
No metabolic impact of surgical normalization of hyperandrogenism in postmenopausal women with ovarian androgen-secreting tumours. Clin Endocrinol (Oxf) (2013) 0.79
Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J Clin Endocrinol Metab (2013) 0.79
Parallel variations of insulin-like peptide 3 (INSL3) and antimüllerian hormone (AMH) in women with the polycystic ovary syndrome according to menstrual cycle pattern. J Clin Endocrinol Metab (2013) 0.79
The endocannabinoid system in the regulation of cardiometabolic risk factors. Am J Cardiol (2007) 0.79
Combined aldosterone and cortisol secretion by adrenal incidentaloma. Int J Surg Pathol (2011) 0.79
Efficacy of octreotide-LAR in dieting women with abdominal obesity and polycystic ovary syndrome. J Clin Endocrinol Metab (2005) 0.78
High serum concentration of total inhibin in polycystic ovary syndrome. Fertil Steril (2008) 0.78
The unrelenting fall of the pharmacological treatment of obesity. Endocrine (2013) 0.78
Cross-talk between adipose tissue and the HPA axis in obesity and overt hypercortisolemic states. Horm Mol Biol Clin Investig (2014) 0.77
Feeding disorders and obesity. Curr Top Behav Neurosci (2009) 0.76
Glucose tolerance, insulin secretion and insulin sensitivity in polycystic ovary syndrome. JOP (2002) 0.76
Obesity-related proliferative diseases: the interaction between adipose tissue and estrogens in post-menopausal women. Horm Mol Biol Clin Investig (2015) 0.76
The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease. Eur J Endocrinol (2005) 0.75
Polycystic ovary syndrome in adolescents: pathophysiology and treatment implications. Treat Endocrinol (2003) 0.75
The biological balance between psychological well-being and distress: a clinician's point of view. Psychother Psychosom (2006) 0.75
Obesity. J Assoc Physicians India (2015) 0.75
Adrenal Gland. J Assoc Physicians India (2015) 0.75
Endocrine International Congresses. J Assoc Physicians India (2015) 0.75
Pituitary. J Assoc Physicians India (2015) 0.75
Application of Diagnostic Techniques to Endocrinology. J Assoc Physicians India (2015) 0.75
Genitalia and Infertility. J Assoc Physicians India (2015) 0.75
Application of Diagnostic Techniques to Endocrinology. J Assoc Physicians India (2015) 0.75
Thyroid: From Hellenistic Greece to Renaissance. J Assoc Physicians India (2015) 0.75
Genitalia and Infertility. J Assoc Physicians India (2015) 0.75
Thyroid: From 16th to 20th Century. J Assoc Physicians India (2015) 0.75